Adjusted EBITDA grew 19% in Q3 and 25% year-to-date Cash from operations grew 67% in Q3 and 121% year-to-date Announced new credit facility with lower rates, increased flexibility and reduced F/X risk Bempedoic acid approval expected in Q4 2025; preparations underway for Q2 2026 launch TORONTO , Nov. 13, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing... Read More

TORONTO , Oct. 30, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release financial results for the three and nine months ended September 30, 2025 , on Thursday, November 13, 2025 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian , Chief Executive Officer; John Hanna , Chief Financial... Read More

TORONTO , Oct. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ: AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress ("CCC") in Quebec City , from October 23... Read More

CAD $79 million term loan replaces USD $56 million term loan CAD $107 million (~USD $77.5 million ) total facility provides enhanced financial flexibility CAD-denominated facility reduces FX exposure and lowers interest rate TORONTO , Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and... Read More

TORONTO , July 31, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release financial results for the three and six months ended June 30, 2025 , on Thursday, August 14, 2025 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian , Chief Executive Officer; John Hanna , Chief Financial Officer; and... Read More

Vascepa is now available to more than 95% of Canadians who are eligible and covered by a public plan or private insurance TORONTO , July 2, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the... Read More

TORONTO , June 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 20 , 2025. A total of 16,073,335 Common Shares, or 50.81% of the total Common Shares issued and outstanding,... Read More

TORONTO , April 28, 2025 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Brian Walsh , Chief Commercial Officer, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, which takes place May 5-6, 2025 at the Metro Toronto Convention Centre, in... Read More

TORONTO , April 24, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2025 financial results on Thursday, May 8, 2025 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian , Chief Executive Officer; John Hanna , Chief Financial Officer; and Brian Walsh , Chief Commercial Officer.... Read More

2024 Adjusted EBITDA, excluding royalty revenue, grew 42% driven by growth in promoted products and reduction in operating expenses Vascepa revenue in C$ grew 29% in Q4 2024 and generated its first profitable quarter since launch Paid down $21 million in debt in 2024, increasing capital allocation flexibility Launching normal course issuer bid in March 2025 TORONTO , March 13, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the... Read More

TORONTO , March 13, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Christine Elliott has been appointed to the Company's Board of Directors (the "Board"), effective immediately. Ms. Elliott served as Ontario's Deputy Premier and Minister of Health from 2018... Read More

TORONTO , Feb. 27, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2024 financial results on Thursday, March 13, 2025 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian , Chief Executive Officer; John Hanna , Chief Financial Officer; and Brian Walsh , Chief Commercial... Read More

TORONTO , Nov. 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and nine months ended September 30, 2024 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q3 2024 revenue... Read More

TORONTO , Oct. 24, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7, 2024 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer, and Mr. John Hanna , Chief Financial Officer. Slides to accompany... Read More

TORONTO , Aug. 28, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian , Chief Executive Officer, will present at H.C. Wainwright's 26th Annual Global Investment Conference, which takes place September 9-11, 2024 at the Lotte New York Palace Hotel... Read More

TORONTO , Aug. 8, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2024 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q2 2024 revenue was... Read More

With the addition of Alberta's public plan, Vascepa will be available to more than 90% of Canadians who are eligible and covered by a public or private plan. TORONTO , July 29, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product... Read More

TORONTO , July 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 fiscal 2024 financial results on Thursday, August 8, 2024 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. John Hanna , Interim Chief Financial Officer. Slides to accompany... Read More

Total consideration of up to $45.75 million , which consists of upfront cash, sales-based milestone payments and DRI Healthcare's assumption of future milestone payment obligations HLS will use the upfront cash proceeds to pay down debt 2024 revenue and Adjusted EBITDA guidance is updated to reflect effective sale date of June 28, 2024 TORONTO , July 2, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS),... Read More

TORONTO , June 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024 . A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows: Name of... Read More

Real world evidence demonstrates pharmaceutical support programs positively impact patient persistence with clozapine treatment Study highlights significant differences in clozapine persistence rates across pharmaceutical support programs DORVAL, QC , May 28, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric... Read More

TORONTO , May 9, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three-month period ended March 31, 2024 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q1 2024 revenue was $12.5... Read More

TORONTO , April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday, May 9, 2024 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. John Hanna , Interim Chief Financial Officer. Slides to accompany... Read More

TORONTO , April 9, 2024 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian , Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place April 16-17, 2024 at the Metro Toronto Convention Centre, North... Read More

Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) TORONTO , April 8, 2024 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease,... Read More

TORONTO , March 14, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three- and twelve-month periods ended December 31, 2023 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Fiscal... Read More

TORONTO , Feb. 29, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2023 financial results on Thursday, March 14, 2024 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. John Hanna , Interim Chief Financial Officer. Slides to... Read More

Public reimbursement for Vascepa is now available in Ontario , Quebec , British Columbia , Saskatchewan , New Brunswick , Northwest Territories , Veterans Affairs and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples. Approximately 14% of all Canadians live in British Columbia 1 . Pacific Blue Cross, British Columbia's largest private health plan, also expected to reimburse Vascepa... Read More

John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO , Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Tim Hendrickson is stepping down as CFO to pursue other interests and John Hanna , currently a director of the Company,... Read More

TORONTO , Nov. 9, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three- and nine-month periods ended September 30, 2023 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. RECENT HIGHLIGHTS Q3... Read More

TORONTO , Oct. 26, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9, 2023 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. Tim Hendrickson , Chief Financial Officer. Slides to accompany... Read More

TORONTO , Sept. 6, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Craig Millian , Chief Executive Officer, will present at H.C. Wainwright's 25th Annual Global Investment Conference, which takes place September 11-13, 2023 at the Lotte New York Palace Hotel in New York City . HLS will... Read More

Term is extended, borrowing capacity increases, financial flexibility improves, and interest rates remain relatively unchanged. TORONTO , Aug. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces an extension to its credit agreement, senior secured term loan, revolver facility and expansion facility (the... Read More

TORONTO , Aug. 10, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and six-month periods ended June 30, 2023 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Q2 2023 revenue was $16.4 million and Adjusted... Read More

TORONTO , Aug. 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. Tim Hendrickson , Chief Financial Officer. Slides to accompany... Read More

John Welborn, Jr. is appointed Chair of the Board, succeeding Greg Gubitz , who is retiring John Hanna is appointed to the HLS Board as an independent director TORONTO , June 22, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces today that Mr. John Hanna has been appointed to the Board of Directors (the "Board"), while Greg Gubitz , Chair of the Board, is retiring from the Board. John Welborn ,... Read More

TORONTO , June 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 16, 2023 . A total of 28,831,784 Common Shares, or 89.12% of the total Common Shares issued and outstanding, were voted based on proxies and votes... Read More

HLS Directors J. Spencer Lanthier and Don DeGolyer will not be standing for re-election at the 2023 AGM Director Greg Gubitz to retire following 2023 AGM and Polar nominee to be appointed to the Board TORONTO , June 8, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces today that J. Spencer Lanthier and Don DeGolyer will not be standing for re-election to the HLS board of directors (the "Board")... Read More

TORONTO , May 11, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2023 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. KEY HIGHLIGHTS Appointed Craig Millian as Chief Executive Officer of the... Read More

TORONTO , May 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2023 financial results on Thursday, May 11, 2023 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer and Mr. Tim Hendrickson , Chief Financial Officer. Slides to accompany... Read More

TORONTO , April 21, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that Tim Hendrickson , Chief Financial Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place Tuesday April 25 - Wednesday April 26 , 2023 at the Metro Toronto Convention Centre, North... Read More

• Craig Millian to replace retiring CEO, Gilbert Godin , on May 1, 2023 TORONTO , April 17, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces the appointment of Craig Millian as Chief Executive Officer ("CEO") of the Company, effective May 1, 2023 , concurrent with the retirement of Gilbert Godin.... Read More

TORONTO , March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and twelve-month periods ended December 31, 2022 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. Q4 & FISCAL 2022 FINANCIAL HIGHLIGHTS 2022 revenue of... Read More

TORONTO , March 2, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and Fiscal 2022 financial results on Thursday, March 16, 2023 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin , Chief Executive Officer and Mr. Tim Hendrickson , Chief Financial Officer. Slides to accompany... Read More